AB&B Bio-Tech Co. Ltd. JS Reports 919% Surge in Revenue to RMB 71.1 Million for H1 2025, Narrows Loss to RMB 121.5 Million, EPS at RMB (0.34)
AB&B Bio-Tech Co. Ltd. JS has announced its unaudited interim results for the six months ended June 30, 2025. The company reported a significant increase in revenue, which rose from RMB7.0 million in the first half of 2024 to RMB71.1 million in the same period of 2025. This increase is attributed to higher sales of quadrivalent subunit influenza vaccines and adjustments made to the estimated sales return for 2024. The cost of sales decreased by 18.3%, from RMB12.6 million in 2024 to RMB10.3 million in 2025, aligning with enhanced inventory management. Consequently, the company achieved a gross profit of RMB60.8 million, a significant turnaround from the gross loss of RMB5.6 million reported in 2024. However, the loss for the period was RMB121.5 million, compared to RMB155.8 million in the previous year. Founded in 2015, AB&B Bio-Tech is a China-based vaccine company focused on the research, development, manufacturing, and commercialization of innovative and traditional vaccines using new technical methods.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.